Insider Selling at Recursion Pharmaceuticals Inc.: CFO Sells 50,000 Shares
Recent SEC filings reveal that Michael Secora, Chief Financial Officer of Recursion Pharmaceuticals Inc (NASDAQ: RXRX), sold 50,000 shares of the company on March 13, 2024. On the valuation front, Recursion Pharmaceuticals Inc.’s shares were trading at $10.74 on the day of the recent insider sale, resulting in a market capitalization of approximately $2.53 billion. Therefore, the transaction amounted to a total sale of $537,000.
Michael Secora’s recent sale of shares adds to a trend of insider selling activity at Recursion Pharmaceuticals Inc. Over the past year, Secora has divested a total of 500,000 shares without making any share purchases, highlighting a consistent pattern of insider selling.
Analysis of the insider transaction history for Recursion Pharmaceuticals Inc. reveals a notable absence of insider purchases over the past year, contrasting with 70 insider sells during the same period, indicating a prevailing trend of insider selling.
Recursion Pharmaceuticals Inc. is a pioneering biotechnology company leveraging an AI-powered platform to revolutionize drug discovery. With a mission to decode biology and enhance lives through innovative treatments, the company operates at the forefront of scientific advancement.
Have you read?
Ranked: The most and least expensive US states to retire in 2024.
The Most (And Least) US States For A Family Of Four, 2024.
The Most (And Least) Costly US States For Single Workers, 2024.
These Are The 100 Best U.S. Cities for First-Time Homebuyers for 2024.
American News Brands For CEOs: Top 20 news websites in the United States for 2024.
